F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA
18.6.2019 14:00:00 EEST | Business Wire | Press release
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.
Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships.
Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a fully-fledged clinical-stage, international business. The company’s pipeline of promising bispecific antibodies has the potential to address the growing need for, and commercial opportunity from, more efficacious therapies for cancer patients. I am excited to join the management team of this next-generation immunotherapy business.”
Eliot Forster, CEO of F-star, said: “We believe Darlene’s strong commercial and capital markets experience from within the life sciences sector will play a critical role in our transition and I’m delighted that she has joined the company. Tolga’s expertise and company knowledge continues to be vital to our success as we work towards realising our ambition to bring new drugs to cancer patients as quickly as we can.”
To support F-star’s international expansion strategy, the company has also established US operations based in Cambridge, MA. Research operations will continue at the company’s site in Cambridge, UK, while the US office will support the growth of F-star’s in-house financial, clinical and regulatory activities.
F-star has also appointed Lindsey Trickett as Vice President of Investor Relations and Communications. Lindsey brings with her a wealth of experience in investor relations and antibody drug development. She joins F-star from Intellia Therapeutics, Inc., where she served as a Vice President of Investor Relations. Previously, Lindsey held senior IR and strategic marketing positions at AstraZeneca plc and spent over a decade in roles of increasing responsibility at MedImmune, LLC/AstraZeneca plc.
Both Darlene and Lindsey will be based out of F-star’s US office.
- ENDS -
About F-star Therapeutics Ltd
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for cancer patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005498/en/
Contact information
For investor enquiries:
Lindsey Trickett
VP
Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
Consilium
Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel:
+44 (0)20 3709 5700
E-mail:
F-star@consilium-comms.com
For
media enquiries
Pierre Peotta
Communications Manager
+44
(0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
US
Catherine
London, US President
Tel: +1 917-763-2709
E-mail: F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sinopec Receives CSR Award at Sino-European ESG Conference in Germany1.7.2026 16:38:00 EEST | Press release
China Petroleum & Chemical Corp. (Sinopec) has received the Corporate Social Responsibility Best Practice Award at the 3rd Sino-European Corporate ESG Best Practice Conference in Mainz, Germany, for its case study on carbon footprint management and low-carbon development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701696760/en/ Huang Yiyang (L), Chinese Consul General in Frankfurt, presents the award to a representative of Sinopec. The conference jury said Sinopec has developed a carbon management framework centered on product carbon footprint management, covering the full product life cycle while aligning with both Chinese and European standards. It cited the company’s work with German chemical producer BASF to achieve mutual recognition of carbon footprint accounting methodologies as a milestone that could support greener cooperation across international industrial supply chains. According to the jury, Sinopec’s eff
Vercel and Mercedes-AMG PETRONAS Formula One Team Announce Multi-Year Strategic Partnership1.7.2026 16:30:00 EEST | Press release
Today Vercel, the agentic infrastructure company, announced a new multi-year deal with the Mercedes-AMG PETRONAS Formula One Team. Starting with the British Grand Prix July 2 – 5 2026, Vercel branding will appear on the Mercedes-AMG PETRONAS Formula One Team race cars as the partnership begins its first chapter, before expanding significantly across the team ecosystem from 2027 onward. The partnership includes global branding rights, premium hospitality experiences, customer engagement, content creation, and technical collaborations, including plans to evolve the team’s digital platforms to Vercel. “Formula One is where every millisecond matters, every decision counts, and continuous innovation is fundamental to success. Vercel shares that same philosophy,” said Richard Sanders, Chief Commercial Officer, Mercedes-AMG PETRONAS Formula One Team. “The Vercel platform is helping organizations around the world build faster, perform better, and innovate with confidence. We are excited to wel
OXMIQ Raises $35 Million to Scale OxCore™ Architecture1.7.2026 16:15:00 EEST | Press release
OXMIQ Labs Inc., a unified GPU and AI architecture company founded by Raja Koduri, today closed its $35 million Series A financing, bringing the company’s total capital raised to $60 million. The funding will scale OxCore™, OXMIQ’s licensable GPU architecture that allows semiconductor companies and AI system builders to build custom AI silicon without a full chip program. The round was co-led by Fundomo and Samsung Catalyst Fund, with participation from MediaTek, AM Intelligence Labs, Pegatron Venture Capital, CDIB-TEN, Darwin Ventures, and Morgan Creek Digital, among other financial and strategic investors. OXMIQ’s expertise spans the full AI stack, from renewable power and data center infrastructure to silicon IP, electron-to-token machines (ETMs™), along with the software that runs AI factories and agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701241910/en/ OXMIQ Funding raised to date of $60M after current $3
SamanTree Medical’s Histolog ® Scanner Technology Featured in 13 Publications in Special BJU International Issue on Confocal Microscopy in Urology1.7.2026 16:01:00 EEST | Press release
SamanTree Medical, a global leader in surgical imaging innovation, today announced that Histolog Scanner confocal microscopy technology has been featured in 13 peer-reviewed clinical papers in a special issue of BJU International, one of the world’s leading journals in urology. The special edition focuses on a growing body of evidence of the role of confocal microscopy in urologic surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701425845/en/ SamanTree Medical announces that Histolog® Scanner confocal microscopy technology is featured in 13 peer-reviewed clinical papers in a special issue of BJU International. “The special issue represents increasing momentum behind confocal microscopy in urologic surgery,” said Professor Greg Shaw, consultant urologic surgeon at University College London Hospitals (UCLH) and author of several studies in the special issue. “This collection, ranging from radical prostatectomy to eme
Regnology to Acquire Fed Reporter, Accelerating U.S. Leadership and Advancing Regulatory Modernization1.7.2026 16:00:00 EEST | Press release
Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced it has entered into a definitive agreement to acquire Fed Reporter, the market-leading U.S. provider of regulatory reporting solutions for financial institutions of all sizes, including banks, credit unions, and bank holding companies. The acquisition marks a pivotal milestone in Regnology’s U.S. expansion, creating the most comprehensive regulatory reporting coverage across the American financial landscape and extending its reach to more than 4,000 institutions from global banks to community lenders. By combining a proven, cloud-first, agentic-first technology foundation with deeply embedded local expertise, Regnology is uniquely positioned to support more efficient, transparent, and data-driven reporting, while strengthening alignment between financial institutions and supervisory authorities. “This is the next step in our U.S. strategy,” said Rob Mackay, CEO of Regnolog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom